{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:32:01Z","timestamp":1769149921096,"version":"3.49.0"},"reference-count":47,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2020,6,30]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Enzyme-inducing antibacterial drugs can impair the efficacy of hormonal contraceptives. Suspicion that other antibiotics might do likewise led to advice that extra contraceptive precautions should be taken during a course of antibiotics. However, current advice is that the purported interaction does not occur, based on small studies observing few pregnancies, assuming that all women are susceptible, and without measuring unbound hormone concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To test the null hypothesis that antibiotics do not impair the effectiveness of oral contraceptives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A database review of Yellow Card reports to the UK\u2019s Medicines and Healthcare products Regulatory Agency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data<\/jats:title><jats:p>Spontaneous reports of suspected adverse drug reactions in people taking antibacterial drugs (n=74 623), enzyme-inducing medicines (n=32 872), or control medicines (n=65 578).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Reports of the primary outcome\u2014unintended pregnancies; reports of cardiac arrhythmias and headaches (control events); reports of congenital abnormalities (positive control events); and reports of diarrhoea (a possible confounding factor).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with control medicines, unintended pregnancies were seven times more commonly reported with antibiotics and 13 times more commonly reported with enzyme inducers (the positive controls). Congenital abnormalities were reported seven times more often with enzyme inducers but were not more common with antibiotics. Diarrhoea was not a confounding factor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides a signal that antibacterial drugs may reduce the efficacy of hormonal contraceptives. Women taking hormonal contraceptives should be warned that antibiotics may impair their effectiveness. Extra precautions can be taken during a course of antibiotics; an unintended pregnancy is a life-changing event.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjebm-2020-111363","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T04:00:37Z","timestamp":1597809637000},"page":"112-113","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives"],"prefix":"10.1136","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K","family":"Aronson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin E","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2024101904400844000_26.3.112.1","first-page":"1451","article-title":"[Enzyme induction by drugs and hormonal contraception]","volume":"95","author":"Hempel","year":"1973","journal-title":"Zentralbl Gynakol"},{"key":"2024101904400844000_26.3.112.2","unstructured":"Dossetor J . Interactions between the oral contraceptive pill and antibiotics. Br Med J 1975;468."},{"key":"2024101904400844000_26.3.112.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb07299.x"},{"key":"2024101904400844000_26.3.112.4","first-page":"33","article-title":"The effect of ampicillin on oral contraceptive effectiveness","volume":"55","author":"Friedman","year":"1980","journal-title":"Obstet Gynecol"},{"key":"2024101904400844000_26.3.112.5","first-page":"S31","article-title":"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database","volume":"49","author":"Szoka","year":"1988","journal-title":"Fertil Steril"},{"key":"2024101904400844000_26.3.112.6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.1988.tb03341.x","article-title":"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics","volume":"25","author":"Back","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"2024101904400844000_26.3.112.7","unstructured":"MHRA . YellowCard. Available: https:\/\/yellowcard.mhra.gov.uk\/iDAP [Accessed Sep 2018]."},{"key":"2024101904400844000_26.3.112.8","unstructured":"CIOMS Working Group VIII . Practical aspects of signal detection in pharmacovigilance. 14. Geneva: Council for International Organizations of Medical Sciences, 2010."},{"key":"2024101904400844000_26.3.112.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2008.02.020"},{"key":"2024101904400844000_26.3.112.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6673.572"},{"key":"2024101904400844000_26.3.112.11","first-page":"255","article-title":"[The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives]","volume":"25","author":"Reimers","year":"1971","journal-title":"Prax Pneumol"},{"key":"2024101904400844000_26.3.112.12","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(79)90044-5"},{"key":"2024101904400844000_26.3.112.13","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0850189"},{"key":"2024101904400844000_26.3.112.14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2012.01.010","article-title":"Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women","volume":"86","author":"Blode","year":"2012","journal-title":"Contraception"},{"key":"2024101904400844000_26.3.112.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1976.03270130044027"},{"key":"2024101904400844000_26.3.112.16","article-title":"Failure of oral contraceptive with rifampicin","volume":"15","author":"Gupta","year":"1980","journal-title":"Med J Zambia"},{"key":"2024101904400844000_26.3.112.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6424.1125"},{"key":"2024101904400844000_26.3.112.18","doi-asserted-by":"publisher","DOI":"10.1177\/106002808602000511"},{"key":"2024101904400844000_26.3.112.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80010-2"},{"key":"2024101904400844000_26.3.112.20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women","volume":"13","author":"Sekar","year":"2008","journal-title":"Antivir Ther"},{"key":"2024101904400844000_26.3.112.21","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200204150-00007"},{"key":"2024101904400844000_26.3.112.22","doi-asserted-by":"publisher","DOI":"10.1007\/BF01300701"},{"key":"2024101904400844000_26.3.112.23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5694\/j.1326-5377.1989.tb136691.x","article-title":"Inadvertent pregnancies in oral contraceptive users","volume":"150","author":"Kovacs","year":"1989","journal-title":"Med J Aust"},{"key":"2024101904400844000_26.3.112.24","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.4.439"},{"key":"2024101904400844000_26.3.112.25","unstructured":"Midtvedt T . Microbial functional activities. In: Hanson LA , Yolken RH , eds. Probiotics, other nutritional factors, and intestinal microflora. Philadelphia: Lippincott-Raven, 1999: 79\u201396."},{"key":"2024101904400844000_26.3.112.26","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198121010-00003"},{"key":"2024101904400844000_26.3.112.27","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018060-00004"},{"key":"2024101904400844000_26.3.112.28","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90562-L"},{"key":"2024101904400844000_26.3.112.29","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(79)90094-5"},{"key":"2024101904400844000_26.3.112.30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0002-9378(71)90803-9","article-title":"Reduced maternal plasma and urinary estriol during ampicillin treatment","volume":"109","author":"Willman","year":"1971","journal-title":"Am J Obstet Gynecol"},{"key":"2024101904400844000_26.3.112.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5778.48-b"},{"key":"2024101904400844000_26.3.112.32","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9378(73)90569-3","article-title":"Reduction of maternal estrogen excretion by neomycin","volume":"115","author":"Pulkkinen","year":"1973","journal-title":"Am J Obstet Gynecol"},{"key":"2024101904400844000_26.3.112.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5862.369"},{"key":"2024101904400844000_26.3.112.34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-8981(73)90138-1","article-title":"Effect of ampicillin on the urinary output of steroidal hormones in pregnant and non-pregnant women","volume":"45","author":"Trybuchowski","year":"1973","journal-title":"Clin Chim Acta"},{"key":"2024101904400844000_26.3.112.35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9378(76)90096-X","article-title":"Effect of ampicillin administration on estradiol, estriol, and cortisol levels in maternal plasma and on estriol levels in urine","volume":"124","author":"Sybulski","year":"1976","journal-title":"Am J Obstet Gynecol"},{"key":"2024101904400844000_26.3.112.36","unstructured":"World Health Organization . Medical eligibility criteria for contraceptive use. 4th edn, 2009. https:\/\/www.spdc.pt\/files\/publicacoes\/5_11292_2.pdf"},{"key":"2024101904400844000_26.3.112.37","unstructured":"World Health Organization . Medical eligibility criteria for contraceptive use. 5th edn, 2015. https:\/\/www.who.int\/reproductivehealth\/publications\/family_planning\/MEC-5\/en"},{"key":"2024101904400844000_26.3.112.38","first-page":"1","article-title":"Us medical eligibility criteria for contraceptive use, 2016. Morbidity and Mortality Weekly Report (MMWR)","volume":"65","author":"Curtis","year":"2016","journal-title":"Recomm Rep"},{"key":"2024101904400844000_26.3.112.39","unstructured":"Faculty of Sexual and Reproductive Healthcare (FSRH) . Clinical Effectiveness Unit of the FSRH in the UK\u2019s Royal College of Obstetricians and Gynaecologists. Clinical Guidance, January 2011. Available: https:\/\/www.travax.nhs.uk\/media\/14546\/guidance_on_antibiotics_and_chc_feb_2011.pdf [Accessed 10 July 2020]."},{"key":"2024101904400844000_26.3.112.40","unstructured":"Faculty of Sexual and Reproductive Healthcare (FSRH) . FSRH CEU Guidance. Drug interactions with hormonal contraception, 2017. Available: https:\/\/www.fsrh.org\/standards-and-guidance\/documents\/ceu-clinical-guidance-drug-interactions-with-hormonal"},{"key":"2024101904400844000_26.3.112.41","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(90)90290-9"},{"key":"2024101904400844000_26.3.112.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-8532(02)00017-4"},{"key":"2024101904400844000_26.3.112.43","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"2024101904400844000_26.3.112.44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/1471-0528.15027","article-title":"Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review","volume":"125","author":"Simmons","year":"2018","journal-title":"BJOG"},{"key":"2024101904400844000_26.3.112.45","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00001"},{"key":"2024101904400844000_26.3.112.46","doi-asserted-by":"publisher","DOI":"10.1136\/emj.16.4.268"},{"key":"2024101904400844000_26.3.112.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01532-0"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2020-111363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T11:46:54Z","timestamp":1729338414000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2020-111363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,5,21]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjebm-2020-111363"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2020-111363","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}